Patent ID: 6759396
Filing Date: 2004-07-06
Classification: A61K,A61P,Y10S

Abstract:
A composition suitable for the treatment of a disorder involving abnormal skin cell proliferation with comprises the combination of at least one ligand which binds a nuclear receptor of the VDR type, and at least one retinoid which exhibits selective binding affinity for RAR&ggr; receptors relative to RAR&agr; receptors, wherein said retinoid is selected from the group consisting of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid and derivatives thereof, wherein said combination of at said least one ligand which binds to a nuclear receptor of VDR type, and said at least one retinoid which exhibits selective affinity for RAR&ggr; receptors relative to RAR&agr; receptors exhibits synergistic inhibition of skin cell proliferation relative to either of said ligands.